Recent News
ACE-041
Acceleron’s ACE-041 Combined with a VEGF Inhibitor Shows Potent Activity in Preclinical Model of VEGF-Resistant Renal Cell Carcinoma
+ VIEW FULL
Events
Acceleron Secures $30M Private Financing
Products
Our discovery platform is an exceptionally rich source of novel protein therapies to treat patients with life-threatening and debilitating conditions.
+ VIEW PRODUCTS
[ Sotatercept ]
Anemia
[ ACE-536 ]
[ ACE-041 ]
Cancer
[ ACE-031 ]
DMD
[ ACE-661 ]
Bone Loss
2011 Acceleron Pharma. All rights reserved. + PRIVACY POLICY + SITE MAP
